
MesencHyal-T is an early-stage healthtech company focused on revolutionizing cell therapy for bone regeneration. They are developing AI-powered cellular therapies utilizing allogeneic mesenchymal stem cells combined with hyaluronic acid, extracted from umbilical cords. Their solution offers a ready-to-use product without a scaffold, designed for long-term efficacy and safety. The company's mission is to advance regenerative cell therapies for bone injuries, improving healing and quality of life. Their business model includes the sale of cellular therapies and intellectual property licensing opportunities. Key milestones include MVP development, agreement signings with research institutions like CONICET and Hosp. Garrahan, patent applications (Argentina & PCT), and progress towards regulatory approvals.

MesencHyal-T is an early-stage healthtech company focused on revolutionizing cell therapy for bone regeneration. They are developing AI-powered cellular therapies utilizing allogeneic mesenchymal stem cells combined with hyaluronic acid, extracted from umbilical cords. Their solution offers a ready-to-use product without a scaffold, designed for long-term efficacy and safety. The company's mission is to advance regenerative cell therapies for bone injuries, improving healing and quality of life. Their business model includes the sale of cellular therapies and intellectual property licensing opportunities. Key milestones include MVP development, agreement signings with research institutions like CONICET and Hosp. Garrahan, patent applications (Argentina & PCT), and progress towards regulatory approvals.